[{"id":"b5c3553f-fba7-432f-b39c-23725f3d65d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01933516","created_at":"2021-01-18T08:44:31.124Z","updated_at":"2024-07-02T16:37:08.609Z","phase":"Phase 1","brief_title":"GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT01933516","lead_sponsor":"Sandoz","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive • CD20 positive + TMB-L","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD20 positive + TMB-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rixathon (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 08/01/2014","primary_completion_date":" 08/01/2014","study_txt":" Completion: 08/01/2014","study_completion_date":" 08/01/2014","last_update_posted":"2018-07-26"}]